Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab + Weekly Docetaxel in Stage IV NSCLC
NCT02831491Phase 2Withdrawn
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2016
- Primary completion
- Jul 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 2 trial of ramucirumab in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Planned start Nov 2016; status: withdrawn.
02
Drugs
ramucirumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02831491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02831491.